

# Synthesis of novel spiropyrrolizidines as potent antimicrobial agents for human and plant pathogens

Govindasami Periyasami,<sup>a</sup> Raghavachary Raghunathan,<sup>a,\*</sup>  
Gangadharan Surendiran<sup>b</sup> and Narayanasamy Mathivanan<sup>b</sup>

<sup>a</sup>Department of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India

<sup>b</sup>Center for Advanced Studies in Botany, University of Madras, Guindy Campus, Chennai 600 025, India

Received 21 November 2007; revised 14 February 2008; accepted 28 February 2008

Available online 4 March 2008

**Abstract**—A series of novel dispirooxindolopyrrolizidine derivatives have been synthesized through 1,3-dipolar cycloaddition reaction of azomethine ylide generated from proline and isatin with the dipolarophile (*E*)-2-arylidene-1-keto carbazoles. The synthesized cycloadducts were evaluated for antimicrobial activities. Compounds **7d** and **7e** showed relatively good antibacterial and antifungal activities.

© 2008 Elsevier Ltd. All rights reserved.

Functionalized pyrrolidine, pyrrolizidine and oxindole alkaloids constitute a class of compounds with significant biological activity.<sup>1</sup> Spiro compounds represent an important class of naturally occurring substances characterized by highly pronounced biological properties.<sup>2</sup> The spirooxindole ring system forms the core structure of many pharmacological agents and alkaloids. For example, spirotryprostatin A (Fig. 1), a natural product isolated from the fermentation broth of *Aspergillus fumigatus*, has been identified as a novel inhibitor of microtubule assembly.<sup>3</sup> Spirooxindoles have been reported to behave as aldose reductase, poliovirus and rhinovirus 3C-proteinase inhibitors.<sup>4</sup> Moreover, the derivatives of carbazoles show well-known pharmacological activities.<sup>5</sup> It was found to possess antileukemic<sup>6</sup> and anti-HIV activities.<sup>7</sup>

The chemistry of azomethine ylides has gained significance in recent years as it serves as an important route for the construction of nitrogen containing five-membered heterocycles.<sup>8</sup> The 1,3-dipolar cycloaddition of azomethine ylides with olefinic and acetylenic dipolarophiles offers an excellent route for the construction pyrrolizidines.<sup>9</sup> Although there are reports available for the synthesis of substituted pyrrolizidines, there seems to




Figure 1. Spirotryprostatin A.


be no reports to the best of our knowledge for the synthesis of a rare class of dispirooxindolopyrrolizidines having ketocarbazole skeleton. Because of their remarkable biological activities, significant efforts have been devoted to the synthesis of dispiropyrrolizidines.

An effort to synthesize biologically important compounds we have synthesized a rare class of novel spiro heterocycles wherein oxindole, pyrrolizidine and carbazole rings are fused together. The synthesis was accomplished by 1,3-dipolar cycloaddition reaction of azomethine ylide with arylidene-1-keto carbazoles as dipolarophiles. The required dipolarophiles (*E*)-2-arylidene-1-keto carbazoles were prepared by the reaction of 1-keto carbazole<sup>10</sup> with substituted benzaldehydes **4a–g** (Scheme 1).

The reaction of azomethine ylide (generated in situ by decarboxylative condensation of isatin and sarcosine) with the dipolarophiles **4a–g** using dioxane and metha-

**Keywords:** 1,3-Dipolar cycloaddition; Azomethine ylide; Microwave; Pyrrolizidine.

\* Corresponding author. Tel.: +91 44 22202811; fax: +91 44 22300488; e-mail: [ragharaghunathan@yahoo.com](mailto:ragharaghunathan@yahoo.com)



Scheme 1.


nol under reflux condition afforded dispirooxindolopyrrolizidines **7a–g** in good (50–68%) yields (Scheme 2).

The structure of the products was assigned on the basis of their spectral analyses.<sup>11</sup> In particular, the regiochemistry proposed for the product **7a** was decided on the basis of its <sup>1</sup>H NMR spectrum exhibiting a doublet at  $\delta$  4.61 for the benzylic proton. If the other isomer **8a** were formed, one would expect a singlet instead of a doublet. The <sup>13</sup>C NMR spectrum of **7b** showed two peaks at  $\delta$  64.1 and 78.2 ppm for two spirocarbons and at  $\delta$  66.2 for one methine carbon. The oxindole and keto carbazole carbonyl carbons exhibited peaks at  $\delta$  177.3 and 190.8 ppm, respectively. Identical results were obtained for compounds **7b–g**. The structure of **7b** was further confirmed by X-ray (Fig. 2) single crystal analysis.<sup>12</sup>

However, when the above reaction was carried out under solvent-free microwave irradiation (600 W) grinding with K-10 montmorillonite clay, we found that the products **7a–g** were obtained in better yield, 80–95% (Table 1).

In the present study, minimum inhibitory concentration<sup>13</sup> of seven different newly synthesized dispirooxindolopyrrolizidine compounds were evaluated against four human pathogens and two plant fungal pathogens viz. *Proteus vulgaris*, *Proteus mirabilis*, *Staphylococcus aureus*, *Salmonella typhi*, by well diffusion method<sup>14</sup> and two plant fungal pathogens *Fusarium oxysporum*, *Macrophomina phaseolina*, by poison food technique.<sup>15</sup> The compounds at the concentration range 5–200  $\mu\text{g/ml}$  in 0.25% DMSO was used in this study with tetracycline and carbendazim, respectively, for bacteria and fungi being used as control.

**Effect of dispirooxindolopyrrolizidines (7a–g) on the growth of human pathogens:** The MIC of the tested compounds (**7a–g**) against bacterial pathogen ranged from 10 to 65  $\mu\text{g/ml}$ . The compound **7d** was effective in controlling all the pathogens at the lowest concentration ranging from 10 to 35  $\mu\text{g/ml}$ , followed by **7c** and **7e** (15–45 and 25–45  $\mu\text{g/ml}$ ) as compared with control, tetracycline (10–20  $\mu\text{g/ml}$ ). The MIC values are relatively high for **7b**, **7f** and **7g** as compared to control (Table 2).



Scheme 2.




Figure 2. ORTEP diagram of 7b.

Table 1. Synthesis of dispirooxindolopyrrolizidines (7a–g)

Entry	Compound	R	Conventional heating Yield in 6 h (%)	Microwave heating Yield in 10 min (%)
1	7a	H	62	95
2	7b	Me	50	92
3	7c	OMe	65	88
4	7d	Cl	65	94
5	7e	Br	68	95
6	7f	NO <sub>2</sub>	60	90
7	7g	NMe <sub>2</sub>	30	80

Table 2. Effect of dispirooxindolopyrrolizidines (7a–g) on the growth of human pathogens

Compound	Minimum inhibitory concentration (MIC) (μg/ml)			
	<i>Proteus vulgaris</i>	<i>Proteus mirabilis</i>	<i>Streptococcus aureus</i>	<i>Salmonella typhi</i>
7a	30	55	0	20
7b	40	65	45	35
7c	15	25	40	45
7d	10	35	20	30
7e	25	30	45	30
7f	35	55	25	40
7g	45	50	35	35
Tetracycline	15	20	10	15

**Effect of dispirooxindolopyrrolizidines (7a–g) on the mycelial of plant fungal pathogens:** The MIC of the tested compounds (7a–g) against plant fungal pathogens ranged from 25 to 150 μg/ml. The synthesized compound 7e was effective in controlling both fungal pathogens namely *F. oxysporum* and *M. phaseolina* with MIC values of 50 and 25 μg/ml, respectively, followed by 7c (75 and 25 μg/ml) and 7b (75 and 50 μg/ml). Compounds

Table 3. Effect of dispirooxindolopyrrolizidines (7a–g) on mycelial growth of plant fungal pathogens

Fungal pathogens	Minimum inhibitory concentration (MIC) compound (μg/ml)							Carben-dazim
	7a	7b	7c	7d	7e	7f	7g	
<i>Fusarium oxysporum</i>	125	75	75	125	50	75	150	18
<i>Macrophomena phaseolina</i>	50	50	25	75	25	100	75	15

7a, 7d, 7f and 7g inhibit mycelial growth at higher concentration (50–150 μg/ml) compared to control, carben-dazim (ranged 15 and 18 μg/ml) (Table 3).

In conclusion, we have developed an efficient method for the synthesis of dispiropyrrolizidine derivatives by [3+2] cycloaddition methodology. Of the various conditions employed, the solvent-free solid support approach accelerated by microwave irradiation was found to be synthetically useful in achieving high yields. Though all the compounds 7a–g showed antibacterial activity, the compounds 7d, 7c and 7e showed pronounced activity against four human pathogens. Similarly it has been observed that 7e, 7c and 7b exhibited good bioactivity against fungal pathogens.

### Acknowledgments

G.P.S. & Prof. R.R. thanks the Department of Science and Technology (DST), New Delhi, India. We also acknowledge Dr. D. Velmurugan, Department of Crystallography and Bio-Physics, University of Madras, for the X-ray crystal analysis. The authors thank SAIF, IIT, Chennai, for spectral data.

### References and notes

- Alcaide, B.; Almendros, P.; Alonso, J. M.; Aly, M. F. *J. Org. Chem.* **2001**, *66*, 1351.
- James, D. M.; Kunze, H. B.; Faulkner, D. J. *J. Nat. Prod.* **1991**, *54*, 1137.
- Usui, T.; Kondoh, M.; Cui, C. B.; Mayumi, T.; Osada, H. *Biochem. J.* **1998**, *333*, 543.
- Skiles, J. W.; Mc Neil, D. *Tetrahedron Lett.* **1990**, *31*, 7177.
- Albrecht, W. L.; Fleming, R. W.; Horgan, W. S.; Mayer, G. D. *J. Med. Chem.* **1977**, *20*, 364.
- Galski, H.; Sivan, H.; Lazarovici, P.; Nagler, A. *Leuk. Res.* **2006**, *30*, 1151.
- Russel, M. G. N.; Beer, M. S.; Stanton, J. A.; Sohal, B.; Mortishire, S. R. J.; Castro, J. L. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 2491.
- Daly, J. W.; Spande, T. W.; Whittaker, N.; highet, R. J.; Feigl, D.; Noshimori, N.; Tokuyama, T.; Meyers, C. W. *J. Nat. Prod.* **1986**, *46*, 210.
- Padwa, A. In *1,3-Dipolar Cycloaddition Chemistry*; Wiley: New York, 1984; Vol. 1 and 2.
- Andreeva, N. I.; Farmak, T. *Chem. Abstr.* **1957**, *36*, 713.
- General procedure for the synthesis of dispirooxindolopyrrolizidines:* A mixture of isatin **5** (1 mmol), proline **6** (1 mmol), and (*E*)-2-aryledene-1-keto carbazole **4a–g** was refluxed in dioxane and methanol (1:1). Completion of the

reaction was evidenced by TLC analysis. The solvent was removed in vacuo. The crude product was subjected to column chromatography using petroleum ether–ethyl acetate (9:1) as an eluent. The products were crystallized from hexane/ethyl acetate (1:1).

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-phenylpyrrolizidine spiro [2',3''] indoline-2''-one (7a).** Pale yellow solid, mp 190 °C;  $\nu_{\max}$  (KBr) 3281, 1702, 1643  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  1.48–1.51 (m, 1H); 1.80–1.82 (m, 1H); 2.50–2.78 (m, 7H); 3.00–3.02 (m, 1H); 3.17–3.20 (m, 1H); 4.61 (d, 1H,  $J$  = 11.6 Hz); 6.81–7.50 (m, 13H, ArH); 9.98 (s, 1H, NH); 10.16 (s, 1H, NH).  $^{13}\text{C}$  (100 MHz, DMSO- $d_6$ ):  $\delta$  18.4, 20.8, 21.0, 28.3, 32.2, 53.7, 64.1, 66.2, 78.2, 110.2, 112.7, 119.5, 120.9, 121.0, 124.8, 126.4, 127.4, 128.0, 128.9, 129.0, 129.6, 129.7, 131.3, 133.9, 136.4, 138.7, 142.0, 177.3, 190.8; EI-MS  $m/z$  473.5 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{31}\text{H}_{27}\text{N}_3\text{O}_2$ : C, 78.62; H, 5.75; N, 5.76. Found: C, 78.81; H, 5.59; N, 5.81.

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-(p-methyl)phenyl pyrrolizidine spiro [2',3''] indoline-2''-one (7b).** Pale yellow solid, mp 195 °C;  $\nu_{\max}$  (KBr) 3283, 1705, 1639  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  1.51–1.54 (m, 1H); 1.81–1.83 (m, 1H); 2.31 (s, 3H); 2.58–2.83 (m, 7H); 3.03–3.06 (m, 1H); 3.22–3.25 (m, 1H); 4.66 (d, 1H,  $J$  = 11.6 Hz); 6.64–7.51 (m, 13H, ArH); 10.12 (s, 1H, NH); 10.38 (s, 1H, NH).  $^{13}\text{C}$  (100 MHz, DMSO- $d_6$ ):  $\delta$  18.4, 20.9, 21.0, 24.5, 28.5, 31.63, 53.7, 64.6, 66.2, 74.7, 110.2, 119.5, 120.9, 121.0, 124.8, 124.9, 126.4, 127.5, 128.0, 128.9, 129.4, 129.6, 131.3, 133.9, 136.4, 138.7, 142.0, 177.3, 190.8; EI-MS  $m/z$  487.5 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{32}\text{H}_{29}\text{N}_3\text{O}_2$ : C, 78.82; H, 5.99; N, 8.62. Found: C, 78.75; H, 6.21; N, 8.

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-(p-methoxy) phenyl pyrrolizidine spiro [2',3''] indoline-2''-one (7c).** Pale yellow solid, mp 260 °C;  $\nu_{\max}$  (KBr) 3285, 1708, 1640  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.50–1.52 (m, 1H); 1.82–1.85 (m, 1H); 2.51–2.78 (m, 7H); 3.00–3.11 (m, 1H); 3.19 (m, 1H); 3.80 (s, 3H); 4.51 (d, 1H,  $J$  = 11.5 Hz); 6.71–7.35 (m, 12H, ArH); 9.91 (s, 1H, NH); 10.22 (s, 1H, NH).  $^{13}\text{C}$  (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  17.8, 20.8, 21.0, 28.5, 31.6, 53.7, 58.7, 64.2, 66.2, 74.3, 111.8, 119.5, 120.6, 121.0, 124.8, 124.9, 126.4, 127.5, 128.8, 129.0, 129.6, 129.7, 130.9, 133.9, 136.4, 138.7, 142.0, 156.8, 177.3, 191.0; EI-MS  $m/z$  503.5 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{32}\text{H}_{29}\text{N}_3\text{O}_3$ : C, 76.32; H, 5.80; N, 8.34. Found: C, 76.29; H, 5.91; N, 8.4.

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-(p-chloro) phenyl pyrrolizidine spiro [2',3''] indoline-2''-one (7d).** Pale yellow solid, mp 216 °C;  $\nu_{\max}$  (KBr) 3290, 1702, 1648  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  1.36–1.38 (m, 1H); 1.78–1.79 (m, 1H); 2.48–2.65 (m, 7H); 3.04–3.06 (m, 1H); 3.14–3.17 (m, 1H); 4.61 (d, 1H,  $J$  = 11.6 Hz); 6.92–7.58 (m, 12H, ArH); 9.98 (s, 1H, NH); 10.31 (s, 1H,

NH).  $^{13}\text{C}$  (100 MHz, DMSO- $d_6$ ):  $\delta$  18.1, 20.8, 21.1, 28.5, 31.6, 53.7, 64.5, 68.2, 75.8, 111.2, 118.7, 120.6, 121.5, 124.6, 124.9, 126.4, 127.3, 128.1, 128.9, 129.1, 129.6, 129.7, 131.3, 135.9, 138.7, 142.1, 178.1, 192.6; EI-MS  $m/z$  508.0 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{31}\text{H}_{26}\text{ClN}_3\text{O}_2$ : C, 73.29; H, 5.16; N, 8.27. Found: C, 73.48; H, 5.29; N, 8.38.

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-(p-bromo) phenyl pyrrolizidine spiro [2',3''] indoline-2''-one (7e).** Pale yellow solid, mp 200 °C;  $\nu_{\max}$  (KBr) 3288, 1710, 1645  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.35–1.36 (m, 1H); 1.75–1.77 (m, 1H); 2.50–2.61 (m, 7H); 3.09–3.12 (m, 1H); 3.16–3.18 (m, 1H); 4.68 (d, 1H,  $J$  = 11.6 Hz); 6.96–7.61 (m, 12H, ArH); 10.2 (s, 1H, NH); 10.31 (s, 1H, NH).  $^{13}\text{C}$  (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  18.4, 20.8, 21.1, 28.4, 31.6, 52.9, 64.5, 67.6, 79.8, 110.8, 119.5, 120.7, 121.5, 124.6, 124.9, 126.6, 127.4, 128.1, 128.3, 129.4, 129.6, 129.7, 130.7, 133.1, 138.7, 142.1, 177.3, 191.0; EI-MS  $m/z$  552.4 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{31}\text{H}_{26}\text{BrN}_3\text{O}_2$ : C, 67.40; H, 4.74; N, 7.61. Found: C, 67.72; H, 5.02; N, 7.83.

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-(p-nitro) phenyl pyrrolizidine spiro [2',3''] indoline-2''-one (7f).** Pale yellow solid, mp 212 °C;  $\nu_{\max}$  (KBr) 3293, 1706, 1651  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz, DMSO- $d_6$ ):  $\delta$  1.57–1.60 (m, 1H); 1.85–1.87 (m, 1H); 2.56–2.78 (m, 7H); 3.11–3.13 (m, 1H); 3.30–3.31 (m, 1H); 4.97 (d, 1H,  $J$  = 11.7 Hz); 6.92–7.63 (m, 12H, ArH); 10.13 (s, 1H, NH); 10.61 (s, 1H, NH).  $^{13}\text{C}$  (100 MHz, DMSO- $d_6$ ):  $\delta$  18.4, 20.9, 21.1, 28.4, 31.4, 53.7, 64.2, 66.2, 78.6, 110.2, 112.7, 119.6, 120.9, 121.1, 124.8, 126.4, 127.4, 128.0, 128.9, 129.0, 129.4, 129.7, 131.3, 136.4, 138.7, 142.1, 178.6, 191.2; EI-MS  $m/z$  518.5 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{31}\text{H}_{26}\text{N}_4\text{O}_4$ : C, 71.80; H, 5.05; N, 10.80. Found: C, 71.68; H, 5.26; N, 10.92.

**1,2,3,4-Tetrahydro-1-ketocarbazole spiro [2,3']-4'-(p-N,N-dimethyl) phenyl pyrrolizidine spiro [2',3''] indoline-2''-one (7g).** Pale yellow solid, mp 186–188 °C;  $\nu_{\max}$  (KBr) 3289, 1711, 1650  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  1.32–1.35 (m, 1H); 1.71–1.73 (m, 1H); 2.48–2.51 (m, 7H); 2.61 (s, 6H); 3.01–3.05 (m, 1H); 3.11–3.25 (m, 1H); 4.53 (d, 1H,  $J$  = 11.4 Hz); 6.86–7.61 (m, 12H, ArH); 9.95 (s, 1H, NH); 10.31 (s, 1H, NH).  $^{13}\text{C}$  (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  18.40, 20.8, 21.0, 28.5, 31.6, 40.5, 53.7, 64.5, 66.2, 80.1, 110.9, 114.2, 119.6, 120.8, 121.1, 125.6, 126.8, 127.4, 127.8, 128.1, 128.9, 129.3, 130.7, 131.1, 138.4, 142.2, 143.1, 172.9, 191.5; EI-MS  $m/z$  516.6 ( $\text{M}^+$ ). Anal. Calcd for  $\text{C}_{33}\text{H}_{32}\text{N}_4\text{O}_2$ : C, 76.72; H, 6.24; N, 10.84. Found: C, 7.

12. The coordinates were deposited in Cambridge Crystallographic Data Centre (CCDC 666154).
13. Mann, C. M.; Markham, J. L. *J. Appl. Microbiol.* **1998**, *84*, 538.
14. Jenny, M. W. Ed.; Wiley-VCH, 2006, pp 157.
15. Eloff, J. N. *Planta Medica* **1998**, *64*, 711.